We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+20.56%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.36B
AUM Growth
+$814M
(+23%)
Cap. Flow
+$435M
Cap. Flow
% of AUM
9.98%
Top 10 Holdings %
Top 10 Hldgs %
53.12%
Holding
130
New
25
Increased
23
Reduced
18
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BridgeBio Pharma
BBIO
|
+$183M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$135M |
| 3 |
ATNX
Athenex, Inc. Common Stock
ATNX
|
+$65.5M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$44.9M |
| 5 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$37.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
+$89.6M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$76.6M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
+$17.6M |
| 4 |
iRhythm Holdings
IRTC
|
+$15M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$14.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.53% |
| 2 | Financials | 0.76% |
| 3 | Technology | 0.14% |
| 4 | Consumer Discretionary | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$18.2B
| $340M | 7.8% |
4,023,862
+265,200
| +7% | +$21.8M |
|
|
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $304M | 6.97% |
5,775,726
+250,000
| +5% | +$14.4M |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $299M | 6.85% |
2,899,606
+1,735,224
| +149% | +$135M |
|
4
Iovance Biotherapeutics
IOVA
$2.04B
| $292M | 6.7% |
11,915,127
-320,684
| -3% | -$4.83M |
|
|
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
| $268M | 6.16% |
21,509,486
-130,000
| -0.6% | -$1.65M |
|
|
ATNX
6
DELISTED
Athenex, Inc. Common Stock
ATNX
| $188M | 4.31% |
491,106
+236,305
| +93% | +$65.5M |
|
|
7
BridgeBio Pharma
BBIO
$16.4B
| $181M | 4.15% |
+6,706,268
| New | +$183M |
|
|
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
| $168M | 3.85% |
3,507,223
-362,268
| -9% | -$14.6M |
|
9
MeiraGTx Holdings
MGTX
$1.08B
| $156M | 3.57% |
6,007,746
| – | – |
|
|
AMRN
10
Amarin Corp
AMRN
$297M
| $120M | 2.76% |
310,063
-16,985
| -5% | -$6.22M |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $114M | 2.63% |
1,212,731
-58,323
| -5% | -$4.81M |
|
|
QTNT
12
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $101M | 2.31% |
269,726
| – | – |
|
|
ARNA
13
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $80.9M | 1.86% |
1,380,171
-20,000
| -1% | -$1.03M |
|
14
Travere Therapeutics
TVTX
$5.17B
| $75.8M | 1.74% |
3,772,582
+717,875
| +24% | +$14.2M |
|
|
NVRO
15
DELISTED
NEVRO CORP.
NVRO
| $73.8M | 1.69% |
1,137,765
+720,816
| +173% | +$44.9M |
|
16
Crinetics Pharmaceuticals
CRNX
$8.88B
| $64.7M | 1.48% |
2,587,953
| – | – |
|
|
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $55.2M | 1.27% |
1,100,511
+112,000
| +11% | +$5.45M |
|
|
ALBO
18
DELISTED
Albireo Pharma Inc
ALBO
| $54.9M | 1.26% |
1,704,330
| – | – |
|
|
19
Ascendis Pharma A/S
ASND
$16.5B
| $54.5M | 1.25% |
473,475
-639,853
| -57% | -$76.6M |
|
20
Zymeworks
ZYME
$1.62B
| $52.1M | 1.2% |
2,368,890
+1,795,000
| +313% | +$32.9M |
|
|
DOVA
21
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $50.1M | 1.15% |
3,553,060
+427,209
| +14% | +$4.06M |
|
22
Regenxbio
RGNX
$616M
| $49.9M | 1.14% |
970,997
-174,729
| -15% | -$8.72M |
|
23
Merit Medical Systems
MMSI
$4.82B
| $48.7M | 1.12% |
817,209
-235,889
| -22% | -$13.5M |
|
|
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
| $48.1M | 1.1% |
1,038,390
-3,190,510
| -75% | -$89.6M |
|
|
VRAY
25
DELISTED
ViewRay, Inc.
VRAY
| $48.1M | 1.1% |
5,455,243
+649,593
| +14% | +$5.27M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q2 2019 Portfolio in Review
As of Q2 2019, Perceptive Advisors held 130 positions worth $4.36B, up 23% from $3.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Perceptive Advisors deployed $435M of net new capital in Q2 2019, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was BridgeBio Pharma: 6,706,268 shares worth $181M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Array Biopharma Inc, an estimated $89.6M trimmed.
- Perceptive Advisors's largest Q2 2019 buy was BridgeBio Pharma: 6,706,268 shares worth $181M.
- Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q2 2019, an estimated $135M increase.
- Perceptive Advisors's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $89.6M.
- Perceptive Advisors fully exited iRhythm Holdings in Q2 2019, selling an estimated $15M.
- Perceptive Advisors's ten largest holdings make up 53% of its $4.36B portfolio in Q2 2019.
- Perceptive Advisors opened 25 new positions and closed 26 in Q2 2019.
- Perceptive Advisors's portfolio value rose 23% quarter-over-quarter to $4.36B.
Based on Perceptive Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.